Sustained response of three pediatric BRAF                         V600E                          mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy

Stephanie A. Toll; Hung N. Tran; Jennifer Cotter; Alexander R. Judkins; Benita Tamrazi; Jaclyn A. Biegel; Girish Dhall; Nathan J. Robison; Kaaren Waters; Palak Patel; Robert Cooper; Ashley S. Margol

Sustained response of three pediatric BRAF ^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy

Stephanie A. Toll, Hung N. Tran, Jennifer Cotter, Alexander R. Judkins, Benita Tamrazi, Jaclyn A. Biegel, Girish Dhall, Nathan J. Robison, Kaaren Waters, Palak Patel, Robert Cooper, Ashley S. Margol

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAF ^V600E mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAF ^V600E mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAF ^V600E mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.

Original language	English
Pages (from-to)	551-557
Number of pages	7
Journal	Oncotarget
Volume	10
Issue number	4
State	Published - Jan 1 2019

Keywords

BRAF mutation
High-grade glioma
Pediatrics
Targeted therapy

Cite this

Toll, S. A., Tran, H. N., Cotter, J., Judkins, A. R., Tamrazi, B., Biegel, J. A., Dhall, G., Robison, N. J., Waters, K., Patel, P., Cooper, R., & Margol, A. S. (2019). Sustained response of three pediatric BRAF ^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Oncotarget, 10(4), 551-557.

@article{d94c550913354213b5db48d76c90257f,

title = " Sustained response of three pediatric BRAF V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy ",

abstract = " Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAF V600E mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAF V600E mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAF V600E mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.",

keywords = "BRAF mutation, High-grade glioma, Pediatrics, Targeted therapy",

author = "Toll, {Stephanie A.} and Tran, {Hung N.} and Jennifer Cotter and Judkins, {Alexander R.} and Benita Tamrazi and Biegel, {Jaclyn A.} and Girish Dhall and Robison, {Nathan J.} and Kaaren Waters and Palak Patel and Robert Cooper and Margol, {Ashley S.}",

year = "2019",

month = jan,

day = "1",

language = "English",

volume = "10",

pages = "551--557",

journal = "Oncotarget",

issn = "1949-2553",

number = "4",

}

Toll, SA, Tran, HN, Cotter, J, Judkins, AR, Tamrazi, B, Biegel, JA, Dhall, G, Robison, NJ, Waters, K, Patel, P, Cooper, R & Margol, AS 2019, ' Sustained response of three pediatric BRAF ^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy ', Oncotarget, vol. 10, no. 4, pp. 551-557.

Sustained response of three pediatric BRAF ^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy . / Toll, Stephanie A.; Tran, Hung N.; Cotter, Jennifer et al.

In: Oncotarget, Vol. 10, No. 4, 01.01.2019, p. 551-557.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Sustained response of three pediatric BRAF V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy

AU - Toll, Stephanie A.

AU - Tran, Hung N.

AU - Cotter, Jennifer

AU - Judkins, Alexander R.

AU - Tamrazi, Benita

AU - Biegel, Jaclyn A.

AU - Dhall, Girish

AU - Robison, Nathan J.

AU - Waters, Kaaren

AU - Patel, Palak

AU - Cooper, Robert

AU - Margol, Ashley S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAF V600E mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAF V600E mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAF V600E mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.

AB - Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAF V600E mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAF V600E mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAF V600E mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.

KW - BRAF mutation

KW - High-grade glioma

KW - Pediatrics

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85059902778&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85059902778

SN - 1949-2553

VL - 10

SP - 551

EP - 557

JO - Oncotarget

JF - Oncotarget

IS - 4

ER -

Sustained response of three pediatric BRAF ^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy

Abstract

Keywords

Other files and links

Fingerprint

Cite this